Show simple item record

dc.contributor.authorGlatzer, M.
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorDe Ruysscher, D.
dc.contributor.authorWidder, J.
dc.contributor.authorVan Houtte, P.
dc.contributor.authorTroost, E. G. C.
dc.contributor.authorDahele, M. R.
dc.contributor.authorSlotman, B. J.
dc.contributor.authorRamella, S.
dc.contributor.authorPottgen, C.
dc.contributor.authorPeeters, S. T. H.
dc.contributor.authorNestle, U.
dc.contributor.authorMcDonald, F.
dc.contributor.authorLe Pechoux, C.
dc.contributor.authorDziadziuszko, R.
dc.contributor.authorBelderbos, J.
dc.contributor.authorPutora, P. M.
dc.date.accessioned2020-06-16T11:03:15Z
dc.date.available2020-06-16T11:03:15Z
dc.date.issued2020en
dc.identifier.citationM. Glatzer, C. Faivre-Finn, D. De Ruysscher et al. Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practice. Radiother Oncol. 2020.en
dc.identifier.pmid32447035en
dc.identifier.doi10.1016/j.radonc.2020.05.004en
dc.identifier.urihttp://hdl.handle.net/10541/623028
dc.description.abstractBACKGROUND: In limited disease small cell lung cancer (LD-SCLC), the CONVERT trial has not demonstrated superiority of once-daily (QD) radiotherapy (66 Gy) over twice-daily (BID) radiotherapy (45 Gy). We explored the factors influencing the selection between QD and BID regimens. METHODS: Thirteen experienced European thoracic radiation oncologists as selected by the European Society for Therapeutic Radiation Oncology (ESTRO) were asked to describe their strategies in the management of LD-SCLC. Treatment strategies were subsequently converted into decision trees and analysed for agreement and discrepancies. RESULTS: Logistic reasons, patients performance status and radiotherapy dose constraints were the three major decision criteria used by most experts in decision making. The use of QD and BID regimens was balanced among European experts, but there was a trend towards the BID regimen for fit patients able to travel twice a day to the radiotherapy site. CONCLUSION: BID and QD radiotherapy are both accepted regimens among experts and the decision is influenced by pragmatic factors such as availability of transportation.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.radonc.2020.05.004en
dc.titleOnce daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer - Decision criteria in routine practiceen
dc.typeArticleen
dc.contributor.departmentDepartment of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.en
dc.identifier.journalRadiotherapy and Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record